---
title: "Alexion Pharmaceuticals, Inc. v Samsung Bioepis NL B.V. (UPC CoA 402/2024, 30-07-2024)"
description: "The Court of Appeal refused to expedite an appeal against the dismissal of an application for provisional measures."
url: https://pitch.law/academy/upc-court-of-appeal/upc-coa-402-2024-2024-07-30
lang: en
author: "UPC Case Law by Pitch"
editor: "Bart Lieben"
datePublished: 2026-11-18T10:07:11.829Z
dateModified: 2026-11-18T10:07:11.829Z
---

# Alexion Pharmaceuticals, Inc. v Samsung Bioepis NL B.V.

Order of the UPC Court of Appeal of 30 July 2024, UPC CoA 402/2024.

UPC Case Law by Pitch, edited by [Bart Lieben](https://pitch.law/team/bart-lieben) · Published 18-11-2026

## TL;DR

The Court of Appeal refused to expedite an appeal against the dismissal of an application for provisional measures. A patentee's wish for protection as soon as possible, and the claim that the appeal raises a purely legal issue, do not justify cutting the respondent's 15-day period to respond. Parties seeking a faster appeal in provisional-measures cases should expect the Court to protect the respondent's existing time limits.

## Key holding

Under R 9.3(b) RoP, the Court may shorten any time period on a reasoned request by a party, but it must balance the interests of both parties and give due account to due process, including equality of arms. In an appeal against an order referred to in R 220.1(c) RoP, the 15-day period for the statement of response is already relatively short. It will not be shortened merely because the appellant wants patent protection as soon as possible, says the appeal concerns a purely legal issue, or filed its own grounds of appeal early.

## Questions decided

1. When may the Court of Appeal shorten a time period under R 9.3(b) RoP?
2. Do the patentee's interest in quick protection and a 'purely legal' appeal justify expedition?
3. Does filing the grounds of appeal early support a shorter response period for the respondent?
4. Must the respondent be heard before a request for expedition is rejected?

## Case details

- Court: Court of Appeal of the Unified Patent Court, Panel 1c
- Panel: Klaus Grabinski (President of the Court of Appeal); Peter Blok (legally qualified judge and judge-rapporteur); Emanuela Germano (legally qualified judge)
- Date: 30-07-2024
- Case number(s): UPC CoA 402/2024, UPC CFI 123/2024
- Parties: Appellant: Alexion Pharmaceuticals, Inc. (applicant at first instance); Respondent: Samsung Bioepis NL B.V. (defendant at first instance)
- Language of the proceedings: English
- Outcome: The request for expedition was rejected. The order makes no costs order.
- Official text on the court’s website (PDF): https://www.unified-patent-court.org/sites/default/files/files/api_order/CBB0D6EC8FE749D8EA1BF12C1E0703AB_en.pdf

## How to cite

Court of Appeal, Alexion Pharmaceuticals, Inc. v Samsung Bioepis NL B.V., UPC CoA 402/2024, Order of 30 July 2024 (OSCOLA)

## Full summary

Read the full analyses for free — create a free account: https://pitch.law/academy/upc-court-of-appeal/upc-coa-402-2024-2024-07-30

Topics: [Procedure](https://pitch.law/academy/upc-court-of-appeal/topics/procedure)

## In the same case

- [Alexion Pharmaceuticals, Inc. v Samsung Bioepis NL B.V., UPC CoA 402/2024, 20-12-2024](https://pitch.law/academy/upc-court-of-appeal/upc-coa-402-2024-2024-12-20): The Court of Appeal refused Alexion a preliminary injunction against Samsung Bioepis' eculizumab biosimilar Epysqli.

## More on procedure

- [PAUSTIAN & PARTNER Patentanwälte mbB v NUC Electronics Europe GmbH and others, UPC CoA 163/2026, 11-11-2026](https://pitch.law/academy/upc-court-of-appeal/upc-coa-163-2026-2026-11-11): The Court of Appeal granted a patent law firm access to the statements of appeal and statements of grounds of appeal in three closed appeals concerning EP 2 028 981.
- [The Walt Disney Company and others v InterDigital VC Holdings, Inc., UPC CoA 133/2026, 05-11-2026](https://pitch.law/academy/upc-court-of-appeal/upc-coa-133-2026-2026-11-05): A request under R 262A RoP to stop the other party from accessing or using confidential information cannot be made for the first time on appeal for material already filed at first instance.
- [Guardant Health, Inc. v Sophia Genetics SA and others, UPC CoA 49/2026, 05-11-2026](https://pitch.law/academy/upc-court-of-appeal/upc-coa-49-2026-2026-11-05): The Court of Appeal set aside a EUR 600,000 award of representation costs because the successful party had backed it only with invoices reading "supply of legal services" and general assertions about complexity and urgency.
- [Netflix Services Germany GmbH and others v DivX, LLC, UPC CoA 176/2026, 02-11-2026](https://pitch.law/academy/upc-court-of-appeal/upc-coa-176-2026-2026-11-02): The Court of Appeal refused Netflix's request for suspensive effect against the Munich Local Division's infringement decision in favour of DivX, even though the EPO Opposition Division revoked the patent after that decision.
- [Appellant (name not stated) v Amycel, LLC, UPC CoA 935/2025, 02-11-2026](https://pitch.law/academy/upc-court-of-appeal/upc-coa-935-2025-2026-11-02): The Court of Appeal set aside a decision by default of The Hague Local Division and allowed the defendant's application to have it set aside under R 356 RoP.
